Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.

about

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.

P2860

Q47105115-D05744C0-1A78-4C49-B417-85E22B1FC2A7

P2860

Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.

Item

http://www.wikidata.org/entity/Q38316279

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Getting the balance right: adv ...... cytoplasm antibody vasculitis.

@en

type

Item

label

Getting the balance right: adv ...... cytoplasm antibody vasculitis.

@en

prefLabel

Getting the balance right: adv ...... cytoplasm antibody vasculitis.

@en

P1476

Getting the balance right: adv ...... cytoplasm antibody vasculitis.

@en

P2093

Limy Wong

http://www.w3.org/2001/XMLSchema#string

Lorraine Harper

http://www.w3.org/2001/XMLSchema#string

P2860

Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.

Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

P304

i164-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFU406

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

30 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Mark A. Little

P577

2015-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25583294

http://www.w3.org/2001/XMLSchema#string

Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.

about

P2860

P2860

Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698